Targeted Treatment of Soft-Tissue Sarcoma

Overview

Journal J Pers Med

Date 2023 May 27

PMID 37240900

Authors

Anne Iren Riskjell

Vivi-Nelli Makinen

Birgitte Sandfeld-Paulsen

Ninna Aggerholm-Pedersen

Affiliations

Soon will be listed here.

Abstract

: Soft-tissue sarcoma (STS) is a heterogeneous group of sarcomas with a low incidence. The treatment of advanced disease is poor, and mortality is high. We aimed to generate an overview of the clinical experiences with targeted treatments based on a pre-specified target in patients with STS. : A systematic literature search was conducted in PubMed and Embase databases. The programs ENDNOTE and COVIDENCE were used for data management. The literature was screened to assess the article's eligibility for inclusion. : Twenty-eight targeted agents were used to treat 80 patients with advanced STS and a known pre-specified genetic alteration. MDM2 inhibitors were the most-studied drug ( = 19), followed by crizotinib ( = 9), ceritinib ( = 8), and Y-OTSA ( = 8). All patients treated with the MDM2 inhibitor achieved a treatment response of stable disease (SD) or better with a treatment duration of 4 to 83 months. For the remaining drugs, a more mixed response was observed. The evidence is low because most studies were case reports or cohort studies, where only a few STS patients were included. : Many targeted agents can precisely target specific genetic alterations in advanced STS. The MDM2 inhibitor has shown promising results.

References

Yang L, Wu Y, Tang H, Zhao J, Zhao D, Yang S . PET-CT evaluation of the curative effect of crizotinib on malignant myofibroblastoma with rare mutation of ALK R401: a case report and literature review. Onco Targets Ther. 2018; 11:1921-1927. PMC: 5896645. DOI: 10.2147/OTT.S155033. View

Walsh E, Xing D, Lippitt M, Fader A, Wethington S, Meyer C . Molecular Tumor Board Guides Successful Treatment of a Rare, Locally Aggressive, Uterine Mesenchymal Neoplasm. JCO Precis Oncol. 2021; 5. PMC: 8232830. DOI: 10.1200/PO.20.00189. View

Arnaud-Coffin P, Brahmi M, Vanacker H, Eberst L, Tredan O, Attignon V . Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial. Transl Oncol. 2020; 13(12):100870. PMC: 7509228. DOI: 10.1016/j.tranon.2020.100870. View

Kollar A, Jones R, Stacchiotti S, Gelderblom H, Guida M, Grignani G . Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol. 2016; 56(1):88-92. DOI: 10.1080/0284186X.2016.1234068. View

van der Graaf W, Blay J, Chawla S, Kim D, Bui-Nguyen B, Casali P . Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379(9829):1879-86. DOI: 10.1016/S0140-6736(12)60651-5. View

Groisberg R, Hong D, Holla V, Janku F, Piha-Paul S, Ravi V . Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017; 8(24):39254-39267. PMC: 5503611. DOI: 10.18632/oncotarget.16845. View

Somaiah N, Beird H, Barbo A, Song J, Mills Shaw K, Wang W . Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018; 9(28):19891-19899. PMC: 5929434. DOI: 10.18632/oncotarget.24924. View

Doyle L, Nowak J, Nathenson M, Thornton K, Wagner A, Johnson J . Characteristics of mismatch repair deficiency in sarcomas. Mod Pathol. 2019; 32(7):977-987. DOI: 10.1038/s41379-019-0202-3. View

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

10.

Safwat A, Boysen A, Lucke A, Rossen P . Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients. Acta Oncol. 2014; 53(10):1451-4. DOI: 10.3109/0284186X.2014.948062. View

11.

Kerr D, Thompson L, Tafe L, Jo V, Neyaz A, Divakar P . Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall. Am J Surg Pathol. 2021; 45(12):1707-1719. DOI: 10.1097/PAS.0000000000001735. View

12.

Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C . Phase I Study of P-cadherin-targeted Radioimmunotherapy with Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res. 2020; 26(22):5830-5842. DOI: 10.1158/1078-0432.CCR-20-0037. View

13.

Urakawa H, Kawai A, Goto T, Hiraga H, Ozaki T, Tsuchiya H . Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study. Cancer Sci. 2020; 111(9):3303-3312. PMC: 7469808. DOI: 10.1111/cas.14542. View

14.

Jin G, Wang C, Jia D, Qian W, Yin C, Wang D . Next Generation Sequencing Reveals Pathogenic and Actionable Genetic Alterations of Soft Tissue Sarcoma in Chinese Patients: A Single Center Experience. Technol Cancer Res Treat. 2021; 20:15330338211068964. PMC: 8721396. DOI: 10.1177/15330338211068964. View

15.

Elvin J, Gay L, Ort R, Shuluk J, Long J, Shelley L . Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common Alteration. Oncologist. 2017; 22(4):416-421. PMC: 5388371. DOI: 10.1634/theoncologist.2016-0310. View

16.

Brinch C, Aggerholm-Pedersen N, Hogdall E, Krarup-Hansen A . Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) - A systematic review. Crit Rev Oncol Hematol. 2022; 172:103650. DOI: 10.1016/j.critrevonc.2022.103650. View

17.

He M, Abro B, Kaushal M, Chen L, Chen T, Gondim M . Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma. Hum Pathol. 2020; 100:15-23. DOI: 10.1016/j.humpath.2020.04.007. View

18.

Mansfield A, Murphy S, Harris F, Robinson S, Marks R, Johnson S . Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. Ann Oncol. 2016; 27(11):2111-2117. PMC: 5091324. DOI: 10.1093/annonc/mdw405. View

19.

Chen W, Wang H, Jiang D, Luan L, Zhou Y, Hou Y . Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment. World J Surg Oncol. 2021; 19(1):136. PMC: 8091785. DOI: 10.1186/s12957-021-02237-y. View

20.

Kim J, Kim J, Kang H, Park S, Yu J, Lee E . Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets. BMC Med Genet. 2019; 19(Suppl 1):216. PMC: 6311917. DOI: 10.1186/s12881-018-0722-6. View